Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Generex Biotechnology Corp. (OTC: GNBT).

Full DD Report for GNBT

You must become a subscriber to view this report.


Recent News from (OTC: GNBT)

Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA
EVP R&D to be a Presenting Panelist Novel Therapeutics in Cancer Immunotherapy at the Immuno-Oncology Investing & Partnering Forum on August 30 th at 1:30 PM Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT...
Source: Business Wire
Date: August, 27 2018 09:00
Generex Biotechnology Corporation Announces the Filing of a Patent for its New Diagnostic Point-of-Care Platform, the Express II
Hema Diagnostic Systems, LLC dba NuGenerex Diagnostics ( www.hemadiagnosticsystems.com ), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ), announced today the filing of a patent on its new diagnostic qualitativ...
Source: Business Wire
Date: July, 02 2018 09:00
Generex Announces Terry Thompson as Chief Operating Officer
Industry Leader in Pharmacy Benefits Management & Operations to Join Executive Team Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased and proud to announce that Terry Thompson has joined the Company’s executive manageme...
Source: Business Wire
Date: June, 25 2018 09:00
What Would I Like In My Market Top Algorithm?
Because I am a strong advocate of the P/E ratio, and because it has been high for so long, I have written more than one piece arguing that the market is too high, and I have been wrong every time. Well, I don’t know that I am entirely wrong. The market is high by almost any measure, but...
Source: SeekingAlpha
Date: February, 05 2018 08:23
Generex CEO Provides 2017 Year-End Summary to Stakeholders
Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) ( www.generex.com ) today issued the following letter from the Company’s President & Chief Executive Officer, Joseph Moscato, providing his fellow stockholders with a summary of the Compa...
Source: Business Wire
Date: January, 04 2018 08:30
Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018
Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) ( www.generex.com ) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team...
Source: Business Wire
Date: January, 03 2018 11:00
Generex acquires two retail pharmacy operations; shares up 26%
Following through on its strategy to establish a footprint in the U.S. direct-to-consumer pharmaceuticals business, Generex Biotechnology ( OTCQB:GNBT +26% ) acquires two pre-operational retail pharmacy operations: Empire State Pharmacy in New York and Grainland Pharmacy in Kansas. Both ...
Source: SeekingAlpha
Date: January, 03 2018 10:44
Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy
Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) ( www.generex.com ) today announced that it has completed the acquisition of two pre-operational retail pharmacy operations. On December 28, 2017, the Company, through a new wholly-owned subsidi...
Source: Business Wire
Date: January, 03 2018 09:00
Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals
Deal includes milestone payments & royalties Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) ( www.generex.com ) today confirmed its receipt of the $700,000 USD up-front license fee (net of applicable Chinese withholding taxes) payable...
Source: Business Wire
Date: January, 02 2018 09:00
Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans
Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) ( www.generex.com ) today announced that it will hold an investor conference call at 10:30 a.m. Eastern time on Thursday, January 4, 2018 . Dial-in instructions will be issued prior to the date o...
Source: Business Wire
Date: December, 18 2017 09:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-171.241.331.481.19315,901
2018-12-140.941.161.360.94800,476
2018-12-130.780.930.960.78287,713
2018-12-120.750.780.860.75212,260
2018-12-110.880.710.900.71176,341

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17183,144315,70158.0119Short
2018-12-14333,660800,47641.6827Short
2018-12-1397,665287,71333.9453Cover
2018-12-1256,962212,26026.8360Cover
2018-12-1139,792176,34122.5654Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNBT.


About Generex Biotechnology Corp. (OTC: GNBT)

Logo for Generex Biotechnology Corp. (OTC: GNBT)

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity with no deposit in the lungs . The Company s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company s proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD T helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

 

 

 

Current Management

  • Joseph Moscato / CEO
  • Mark Corrao / CFO
  • Mark Fletcher / EVP, General Counsel
    • Mr. Fletcher served as President and Chief Executive Officer of Generex Biotechnology Corporation from September through January , . Mr. Fletcher served as a member of the Board of Directors of Generex from March through January , . Mr. Fletcher was Executive VicePresident and General Counsel of Generex from April until September , and he resumed those roles as of January , . Prior to joining Generex, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. Mr. Fletcher was previously a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto. Mr. Fletcher received his LL.B. from the University of Western Ontario in and was admitted to the Ontario Bar in .
  • Richard David Purcell / SVP, R amp D
  • Andrew Ro / CIO
  • Dr. Jason Bradley Terrell, MD / CSO, CMO
  • Dr. Jacob Dagan / Business Development
  • Joseph Moscato / Chairman
  • Mark Corrao / Chairman
  • Andrew Greene /
  • Dr. Craig Eagle MD / Independent Director
  • Dr. James H. Anderson, Jr., MD / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Dr. Gary H. Lyman, MD, MPH / Independent Director
  • Brian McGee / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Andrew Ro /
  • Lawrence Anthony Salvo /

Current Share Structure

  • Market Cap: $3,355,043 - 03/15/2018
  • Authorized: 2,450,000 - 03/15/2018
  • Issue and Outstanding: 1,065,093 - 03/15/2018

 


Recent Filings from (OTC: GNBT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 18 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 14 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: December, 12 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 11 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 04 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 27 2017

 

 


Daily Technical Chart for (OTC: GNBT)

Daily Technical Chart for (OTC: GNBT)


Stay tuned for daily updates and more on (OTC: GNBT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GNBT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNBT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GNBT and does not buy, sell, or trade any shares of GNBT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/